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Abstract
Lithium is the first-line treatment for bipolar affective disorder (BPAD) but two-thirds of patients respond only partially
or not at all. The reasons for this high variability in lithium response are not well understood. Transcriptome-wide
profiling, which tests the interface between genes and the environment, represents a viable means of exploring the
molecular mechanisms underlying lithium response variability. Thus, in the present study we performed co-expression
network analyses of whole-blood-derived RNA-seq data from n= 50 lithium-treated BPAD patients. Lithium response
was assessed using the well-validated ALDA scale, which we used to define both a continuous and a dichotomous
measure. We identified a nominally significant correlation between a co-expression module comprising 46 genes and
lithium response represented as a continuous (i.e., scale ranging 0–10) phenotype (cor=−0.299, p= 0.035). Forty-
three of these 46 genes had reduced mRNA expression levels in better lithium responders relative to poorer
responders, and the central regulators of this module were all mitochondrially-encoded (MT-ND1, MT-ATP6, MT-CYB).
Accordingly, enrichment analyses indicated that genes involved in mitochondrial functioning were heavily over-
represented in this module, specifically highlighting the electron transport chain (ETC) and oxidative phosphorylation
(OXPHOS) as affected processes. Disrupted ETC and OXPHOS activity have previously been implicated in the
pathophysiology of BPAD. Our data adds to previous evidence suggesting that a normalisation of these processes
could be central to lithium’s mode of action, and could underlie a favourable therapeutic response.
Introduction
Bipolar affective disorder (BPAD) affects at least 2% of
the population and is characterised by recurring episodes
of depression, mania, or mixed affective states1. Mood
stabilising medications are prescribed for most BPAD
patients. These drugs are effective in ameliorating the
symptoms of acute illness episodes2, as well as providing
long-term protection against episode recurrence3.
Lithium is widely considered the ‘gold standard’ mood
stabiliser3,4 due to its uniquely protective effects against
both manic and depressive episodes5, as well as suicide6.
Therefore, lithium is recommended as first-line main-
tenance treatment for BPAD by several clinical practice
guidelines7–10.
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However, the clinical response to lithium is highly
variable between individuals. While many patients achieve
full symptom resolution and long-term recovery, 30%
show only partial response, and a further 30% are con-
sidered poor responders11–13. Evidence from the literature
highlights some potential clinical predictors of a favour-
able vs. poor response to lithium in BPAD. These include
course of illness, age of BPAD onset, number of BPAD
hospitalisations, and pattern of BPAD symptomatol-
ogy14,15. Further, genetic factors are known to explain
some of the clinical variability. ‘Good’ lithium responders
are more likely to come from families with a higher pre-
valence of BPAD, and to have relatives that have also
responded favourably16–18. Previous genetic investigations
including linkage19–21, candidate gene22–24, and genome-
wide association studies (GWAS)25–27 have implicated
multiple genes as candidate mediators of the genetic
component of lithium response, but the vast majority of
these findings have not been replicated28. Most recently, a
GWAS of over 2500 BPAD patients conducted by the
International Consortium on Lithium Genetics (ConLi+-
Gen)29 has implicated an intergenic locus on chromo-
some 21 at genome-wide significance (p < 5 × 10−08) for
association with a quantitative measure of lithium
response. Long intergenic non-coding RNAs (lincRNAs)
reside at this locus, suggesting they may mediate this
association. However, in-depth follow-up functional
characterisation is required before this genome-wide sig-
nificant association can be harnessed to improve our
understanding of the molecular mechanisms underlying
the therapeutic effects of lithium, much less provide any
clinical utility29.
No biological markers currently exist in psychiatric
practice for the purpose of reliably stratifying subgroups
of good vs. poor responders to lithium, at the outset of
therapy. This has multiple implications, including the
potential risk of prolonging clinical symptoms in patients
that are found to respond poorly to lithium and who
might otherwise have responded better to an alternative
drug. Further, because long-term lithium therapy is
associated with potentially serious side effects including
chronic renal failure, hypothyroidism and mortality due to
acute toxicity4, this lack of markers for personalised pre-
scribing puts BPAD patients at additional risk.
Transcriptome-wide profiling using microarray or next
generation RNA-sequencing technology constitutes a
complementary approach towards identifying biological
correlates of lithium response in BPAD, with the potential
to elucidate the underlying mechanisms. Few such studies
to date have been undertaken using patient samples but
rather cultured cells that have undergone immortalisa-
tion30–32. Results so far have implicated, for example,
apoptotic pathways30,31, neutral amino acid transport30,
protein ubiquitination, and protein synthesis32. However,
while providing valuable leads for future research, the
findings of these studies have been compromised by
relatively small sample sizes, associated difficulties with
statistical power and multiple testing, and poor replic-
ability33. Additionally, no previous gene expression study
has measured gene expression correlates of long-term
response to lithium treatment beyond 6 months.
In order to overcome these difficulties in the current
study, we performed weighted gene co-expression net-
work analysis (WGCNA), a hypothesis-free systems biol-
ogy approach that identifies ‘modules’ of co-regulated,
and therefore functionally related, genes in transcriptomic
data sets. Emerging evidence indicates that such an
approach can be advantageous in characterising clinical
phenotypes that are highly complex, polygenic, and het-
erogeneous34–36, even when utilising transcriptomic data
from relatively small sample sizes. Indeed, the recom-
mended minimum sample size to construct a robust
network using WGCNA is just 15–20 (https://labs.
genetics.ucla.edu/horvath/CoexpressionNetwork/
Rpackages/WGCNA/faq.html), while functional term
enrichment and pathway analyses have demonstrated that
co-expression networks constructed using data from
small to moderate sample sizes are biologically
meaningful37,38.
Materials and methods
Sample recruitment and data collection
In all, n= 50 BPAD patients of European ancestry
(Supplementary Table 1) undergoing or who had under-
gone treatment with lithium were recruited from hospitals
across the state of South Australia, Australia, as part of
the ConLi+Gen consortium (Supplementary Informa-
tion)39 and the ongoing University of Adelaide ‘Cognitive
Function and Mood Study’ (CoFaMS, HREC RAH No.
111230). Written informed consent was obtained, after
which lithium treatment response data were collected and
a 10mL blood sample was taken by forearm venipuncture
into Vacutainer EDTA tubes. Whole-blood samples were
then aliquoted into standard Eppendorf tubes; (i) 2 mL
aliquots stored at −80 °C for subsequent genomic DNA
(gDNA) extraction, and (ii) 1 mL aliquots stabilised with
RNAlater™ (Thermo Fisher Scientific, Norwood SA,
Australia) stored at −20 °C for total RNA extraction.
Measurement of lithium treatment response
Lithium treatment response was assessed using a pre-
viously published and validated scale called the ‘Retro-
spective Criteria of Long-Term Treatment Response in
Research Subjects with Bipolar Disorder’ scale, also
known as the ALDA scale13,16. The ALDA scale is
described in more detail in Supplementary Information.
For analyses we directly utilised the total ALDA score
(i.e., range 0–10) as a ‘continuous’ measure of lithium
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treatment response, and we also defined a ‘dichotomous’
variable with an ALDA score cutoff ≥ 5 to represent
‘responders’ vs. ‘non-responders’ (Supplementary
Information).
Experimental procedures
Total RNA purification and quantitation
Total RNA was purified from 1mL human whole blood
(stabilised with RNAlater™ and stored at −80 °C) using
the Ambion™ RiboPure™ RNA Purification Kit, blood
(Thermo Fisher Scientific, Norwood SA, Australia). Pur-
ified total RNA was then immediately quantitated using a
Qubit® 2.0 Fluorometer before storage at −80 °C in 1 μg
aliquots ready for cDNA library preparation. An addi-
tional 10 μL aliquot was also made in order to enable
quantification of RNA integrity number (RIN) using the
Agilent RNA 6000 Nano Kit and an Agilent 2100
Bioanalyzer.
cDNA library preparation and RNA sequencing
cDNA libraries were prepared with 1 μg total RNA
template using the TruSeq Stranded Total RNA with
Ribo-Zero Globin kit (Illumina, Scoresby VIC, Australia).
Libraries were sequenced using the Illumina HiSeq 4000
in 75 bp paired-end read mode.
Bioinformatics procedures and analyses
Processing of RNA sequencing data
Basic quality checks were run using FastQC (Andrews:
http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) followed by adapter and quality (-q option set to
20) trimming with Cutadapt (v1.12) in paired-end mode40.
Remaining reads were pseudoaligned to the human
transcriptome (as per GRCh38.84 GTF file downloaded
from Ensembl on 08/03/2016) and transcript abundances
quantified using Kallisto (v0.44.0)41. The tximport R
package (v1.8.0)42 was then used to summarise transcript
abundances to the gene level.
Gene co-expression network analysis
Gene features with read counts of less than 10 in greater
than 90% of samples were first removed and the
remaining data were regularised log (rlog) transformed
using the DESeq2 R package43. Residuals after adjusting
for age, sex, and RIN were then used as input for weighted
gene co-expression network analysis (WGCNA) using the
WGCNA R package (1.62)34 (Supplementary
Information).
Enrichment and pathway analyses
Functional term and pathway enrichment analyses were
performed using the functional annotation clustering tool
implemented within the recently updated Database for
Annotation, Visualisation, and Integrated Discovery
(DAVID) (v6.8)44 (Supplementary Information). For
additional exploration of gene networks and canonical
pathways associated with lithium response, we used
QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity).
a b
Fig. 1 Identification of a co-expression module relevant for lithium response in BPAD. a Heatmap depicting correlations (p-values) between 23
co-expression module eigengenes (MEs) and lithium response represented as a continuous and a dichotomous phenotype. b Scatterplot with a line
of best fit illustrating the relationship between the royalblue ME and lithium response represented as a continuous phenotype. Colours correspond to
different modules from the overall co-expression network. ME module eigengene
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Results
Network construction and prioritisation of a lithium
response-associated module
We constructed a weighted gene co-expression network
using regularised log transformed count data for 13,659
genes from 50 lithium-treated BPAD cases (see methods
for details of filtering). The resulting network comprised
23 modules ranging in size between 31 and 2912 genes
(Supplementary Fig. 1).
To identify any potential lithium response-relevant
modules within our network, we first computed eigen-
gene composite values (Supplementary Information)35 for
each module within each of our participants and corre-
lated (Spearman’s rank) them with lithium treatment
response scores expressed in both a continuous and
dichotomous fashion (see methods). Overall, we found
one nominally significant correlation between continuous
lithium response and the eigengene of a module denoted
‘royalblue’ (cor=−0.299, p= 0.035) (Fig. 1a). The cor-
relation between this module and dichotomous lithium
response did not meet the nominal significance threshold,
though the trend was similar (cor=−0.249, p= 0.081)
(Fig. 1a). The negative sign on these correlations signifies
that the overall expression profile of this module was
lower in those participants with higher lithium response
scores relative to those with lower scores (Fig. 1a, b).
In addition, the royalblue module was also significantly
correlated with total B scores from the ALDA scale
(Supplementary Information) (cor= 0.322, p= 0.023)
(Supplementary Fig. 2a, b). Notably, there were no addi-
tional nominally significant (p < 0.05) correlations
between the royalblue module and any items from a panel
of assessed psychiatric features (Supplementary Fig. 2d).
Characterisation of a lithium response-associated module
The royalblue module consists of 46 genes in total
(Fig. 2; Supplementary Table 2); 44 of which are protein-
coding while the remaining two encode pseudogenes. A
look at the chromosomal distribution of royalblue module
genes revealed that 35 are autosomal, 2 reside on the X
chromosome, whereas the remaining 9 are all
mitochondrially-encoded (Fig. 2).
Module membership and gene significance
In order to identify the central regulators (or hub genes)
of the royalblue module, we computed the corresponding
module membership (MM) values (see methods). The
gene with the highest absolute MM wasMT-ND1 (MM=
0.939, p= 7.05E-24) (Table 1a), which encodes the
Mitochondrially-Encoded NADH: Ubiquinone Oxidor-
eductase Core Subunit 1 protein. Further, when we pulled
out all genes with a MM> abs(0.8) for inspection (Table
1a), which yielded the top ten genes, the first eight of
them were all mitochondrially-encoded, the ninth was an
autosomal mitochondrial pseudogene (MTATP6P1),
whereas the tenth was an autosomal protein-coding gene
called TSPAN9. Thus, the mitochondrially-encoded genes
within the royalblue module are clearly the central reg-
ulators (Table 1a; Fig. 2).
We also computed gene significance (GS) values to
determine which individual genes within the royalblue
module were most highly correlated with continuous
lithium response. The gene with the highest absolute GS
was CPNE5, which is an autosomal gene encoding a
calcium-dependent lipid-binding protein called Copine 5
(GS=−0.416, p= 0.003) (Table 1b). Of the ten genes
with the highest GS, two of them were mitochondrially-
encoded indicating that the apparent mitochondrial-
related functioning of the royalblue module is also rele-
vant for its association with lithium response (Table 1b).
Accordingly, we observed a small correlation between
absolute MM and absolute GS scores for continuous
lithium response across the royalblue module, though this
did not meet the nominal significance threshold (cor=
0.18, p= 0.23) (Supplementary Fig. 3). Notably, for all but
3 of the 46 royalblue genes (MARCO, AKR1C3, PLD4) the
GS values were negatively signed (Supplementary Table
2), which again indicates that the overall expression pro-
file of the royalblue module was downregulated in parti-
cipants with better lithium response.
Term and pathway enrichment analyses
In order to functionally characterise the royalblue
module we performed term and pathway enrichment
analyses using the functional annotation clustering tool
available at the Database for Annotation, Visualisation
and Integrated Discovery (DAVID) (Supplementary
Information)44. Overall, there were two significant func-
tional annotation clusters with an enrichment score > 1.3
(which corresponds to p < 0.05) (Fig. 3; Supplementary
Table 3).
The top cluster, which had an enrichment score of 4.1,
consisted of 33 annotation terms and was driven primarily
by the mitochondrially-encoded genes within the module.
Among the top annotation terms within this cluster were
multiple mitochondrial-related Uniprot keywords
including ‘Respiratory chain’ (32-fold enrichment), ‘Ubi-
quinone’ (51-fold), and ‘Electron transport’ (20-fold);
while the top functional pathways include ‘Oxidative
phosphorylation’ (16-fold) (KEGG; hsa00190) and
‘Respiratory electron transport’ (21-fold) (Reactome; R-
HSA-611105) (Fig. 3a; Supplementary Table 3). Of par-
ticular note, there was also a gene ontology (GO) cellular
component (CC) term specifically highlighting complex I
of the respiratory chain (29-fold), which was associated
with five paralogous royalblue mitochondrially-encoded
genes (MT-ND1, 2, 3, 4, and 4L).
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The second functional annotation cluster had an
enrichment score of 2.6 and was composed of five
annotation terms in total, all of which indicate a general
overrepresentation of royalblue-encoded proteins loca-
lised to membranes. The fold-enrichments here were
much more subtle, with a range between 1.5- and 2.2-fold.
Notably, the mitochondrially-encoded genes did con-
tribute towards these enrichments though they were not
the main drivers (Fig. 3b; Supplementary Table 3).
To further explore and validate these functional find-
ings, we subjected the royalblue module to Ingenuity®
Pathway Analysis (IPA®). Canonical pathway analysis
confirmed the centrality of mitochondrial mechanisms to
the module, and listed ‘oxidative phosphorylation’ (p=
7.16E-13, 8.3% pathway overlap) and ‘mitochondrial dys-
function’ (4.28E-11, 5.3% pathway overlap) as top hits
(supplementary Table 4). IPA® analysis of functional
networks revealed as top hit a network with the annota-
tions ‘metabolic disease, developmental disorder, heredi-
tary disorder’. This network achieved an IPA® network
score of 35, indicating that the overlap between this
network and the royalblue module genes is highly sig-
nificant (i.e., an IPA® network score of > 2 corresponds to
p < 0.01). Visualisation of this network identified the
downregulation of mitochondrial complex 1 as the central
functional hub within the royalblue module (Fig. 4).
Discussion
To identify biological systems and mechanisms asso-
ciated with lithium response in BPAD, we performed co-
expression network analyses of whole-blood-derived RNA
sequence data from n= 50 BPAD cases with lithium
response data. We identified a module (denoted ‘royal-
blue’) comprising 46 genes that was negatively correlated,
at nominal significance, with lithium response repre-
sented as a continuous phenotype. Functional character-
isation of this module by term enrichment and pathway
analyses revealed that its central regulators (9 out of 46
genes) are mitochondrially-derived, and encode compo-
nents of the electron transport chain (ETC) and oxidative
phosphorylation (OXPHOS) pathway. These mechanisms















































Fig. 2 Network graph summarising the royalblue co-expression module. The royalblue module was visualised according to a prefuse force
directed layout based on weighted correlations between genes. Minor manual changes to node placement were made to maximise clarity. The size
of each node (and node label) reflects absolute module membership (MM) values, with larger nodes corresponding to higher MM values. Node
colour indicates whether royalblue genes were encoded by autosomal (azure), X chromosome (purple), or mitochondrial (red) DNA. Edge width
reflects the weighting of connections between nodes, with thicker edges corresponding to stronger connections
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production of adenosine triphosphate (ATP), the cell’s
primary source of chemical energy45,46.
Reassuringly, the findings from our study are in keeping
with previous literature relating to BPAD and lithium
response. Firstly, numerous gene expression studies in
both peripheral and central tissues have already shown
altered mRNA levels of multiple mitochondrial-related
genes in BPAD patients relative to controls47–49. This
includes a number of the mitochondrially-encoded genes
found to be altered in the present study such as MT-ND2
and MT-ATP6 among others. Secondly, in addition to
evidence from gene expression studies, there are many
other lines of evidence ranging from post-mortem,
genetic, brain imaging, peripheral cell, and animal studies
that point to general mitochondrial dysfunction in the
pathophysiology of BPAD50–52. And thirdly, lithium
treatment has been shown on multiple occasions to
impact mitochondrial functioning, at least in part by
modulating ETC and OXPHOS pathway activity53,54.
Of particular note is a recent landmark study that
generated dentate gyrus (DG) granule cell-like neurons
using induced pluripotent stem cells (iPSCs) collected
from six BPAD patients and four healthy controls55.
RNA-seq analyses of these cells highlighted 45 genes as
Table 1a Top ten genes from the royalblue module with the highest module membership values
Ensembl ID HGNC symbol Chr Description MM p GS p
ENSG00000198888 MT-ND1 MT Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit
1
0.939 7.05E-24 −0.195 0.174
ENSG00000198763 MT-ND2 MT Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit
2
0.929 2.04E-22 −0.209 0.145
ENSG00000198727 MT-CYB MT Mitochondrially-encoded cytochrome b 0.922 2.05E-21 −0.273 0.055
ENSG00000212907 MT-ND4L MT Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit
4L
0.902 3.87E-19 –0.244 0.087
ENSG00000198840 MT-ND3 MT Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit
3
0.890 5.40E-18 –0.264 0.064
ENSG00000198899 MT-ATP6 MT Mitochondrially-encoded ATP synthase 6 0.877 6.98E-17 –0.322 0.023
ENSG00000198712 MT-CO2 MT Mitochondrially-encoded cytochrome c oxidase II 0.827 1.44E-13 –0.229 0.110
ENSG00000198886 MT-ND4 MT Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit
4
0.823 2.19E-13 –0.231 0.106
ENSG00000248527 MTATP6P1 1 Mitochondrially-encoded ATP synthase 6 pseudogene 1 0.807 1.43E-12 –0.157 0.276
ENSG00000011105 TSPAN9 12 Tetraspanin 9 0.803 2.31E-12 –0.275 0.053
MM module membership to the royalblue module, GS gene significance for lithium response represented as a continuous phenotype
Table 1b Top ten genes from the royalblue module with the highest gene significance values
Ensembl ID HGNC symbol Chr Description MM p GS p
ENSG00000124772 CPNE5 6 Copine 5 0.528 8.22E-05 –0.416 0.003
ENSG00000102230 PCYT1B X Phosphate cytidylyltransferase 1, choline, beta 0.777 3.16E-11 –0.341 0.015
ENSG00000105808 RASA4 7 RAS p21 protein activator 4 0.364 0.009 –0.325 0.021
ENSG00000165309 ARMC3 10 Armadillo repeat containing 3 0.695 2.22E-08 –0.324 0.022
ENSG00000198899 MT-ATP6 MT Mitochondrially-encoded ATP synthase 6 0.877 6.98E-17 –0.322 0.023
ENSG00000144668 ITGA9 3 Integrin subunit alpha 9 0.415 0.003 –0.304 0.032
ENSG00000137571 SLCO5A1 8 Solute carrier organic anion transporter family member 5A1 0.550 3.45E-05 –0.285 0.045
ENSG00000136231 IGF2BP3 7 Insulin like growth factor 2 mRNA binding protein 3 0.605 3.26E-06 –0.282 0.047
ENSG00000011105 TSPAN9 12 Tetraspanin 9 0.803 2.31E-12 –0.275 0.053
ENSG00000198727 MT-CYB MT Mitochondrially-encoded cytochrome b 0.922 2.05E-21 –0.273 0.055
MM module membership to the royalblue module, GS gene significance for lithium response represented as a continuous phenotype
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being significantly (FDR < 0.1) differentially expressed
between patients and controls, which included six
mitochondrially-encoded transfer RNAs that were all
enhanced in BPAD neurons. In accordance with this, the
authors observed enhanced mitochondrial membrane
potential (MMP) in BPAD DG-like neurons, which is
indicative of increased mitochondrial functioning.
Crucially, the BPAD patients from this study were
selected based on their known response to lithium treat-
ment; three ‘lithium responders’ (LR) and three ‘non-
responders’ (NR)55. Following chronic lithium treatment,
RNA-seq analyses revealed 560 differentially expressed
genes in LR DG-like neurons relative to control, com-
pared to just 40 genes from the NR group. Further, 84 of
these differentially expressed genes from the LR group
were found to have been rescued by lithium treatment,
including ten mitochondrially-encoded genes that were
downregulated in response to chronic lithium. Strikingly,
7 of these 10 mitochondrial genes belong to the royalblue
module identified in the present study, all of which we
found had lower mRNA expression in better lithium
responders relative to poorer.
Thus, the directionality observed in whole blood in our
study with regards to mitochondrially-encoded gene
expression is consistent with that previously seen in DG-
like neurons derived from iPSCs55. This consistency offers
convincing support for the validity and robustness of our
findings, which is underscored not only by the obvious
difference between the two studies in terms of tissue, but
also the difference in phenotype definition. Indeed, in our
study we utilised the ALDA scale to define lithium
response both as a continuous and a dichotomous vari-
able, where we observed a nominally significant associa-
tion with the continuous phenotype only. In contrast, the
iPSC study used the Clinical Global Impressions Scale to
define a dichotomous phenotype; i.e., LR vs. NR55. How-
ever, it is important to note that only two BPAD patients
in our study achieved a total ALDA score ≥ 7, which
according to ConLi+Gen is the optimum cutoff to define a
dichotomous phenotype39. We, therefore, used a lower
cutoff of 5 (Supplementary Information), which may
explain why we did not observe a significant correlation
with our dichotomous phenotype.
a
b
Fig. 3 Enrichment analyses of royalblue module genes. Bar charts summarising two significant functional annotation clusters indicating
enrichment of a mitochondrial-related genes and b genes encoding membrane proteins. Fold enrichment of individual terms within each cluster is
indicated by bar length, and corresponding uncorrected p-values are indicated to the right of each bar. Note the difference in fold enrichment scale
between a and b panels. UP uniProt, KEGG kyoto encyclopaedia of genes and genomes, EC enzyme commission, GO gene ontology, MF molecular
function, BP biological process, CC cellular component, IntAct molecular interaction database, SEQ sequence annotation
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Fig. 4 Graphic representation of the IPA® top gene network derived from the royalblue module. Green colour indicates reduced gene
expression in better lithium treatment responders, relative to poor responders. Red colour indicates increased gene expression, respectively. The
mitochondrial complex 1 is identified as the central functional hub within the royalblue module
Stacey et al. Translational Psychiatry  (2018) 8:183 Page 8 of 11
Nevertheless, given there is ample precedence for a
relationship between mitochondrial functioning, BPAD,
and lithium response, one of the major questions going
forward is to determine the precise mechanisms under-
lying this relationship. One intriguing line of investigation
points to a possible mediating role for neuronal excit-
ability. Previous studies have reported hyperexcitable
neurons within the VTA and DG of animal models of
BPAD, which is considered to be a potential endophe-
notype of BPAD in humans56,57. In the aforementioned
iPSC study, patch-clamp recordings revealed that iPSC-
derived DG-like neurons from BPAD patients are indeed
hyperexcitable relative to healthy control neurons55.
Furthermore, they also showed that this phenotype could
be selectively rescued by chronic lithium treatment;
though intriguingly this effect was only observed in the LR
neurons, not the NR neurons. Given the authors observed
this exact same pattern with regards to mitochondrially-
encoded mRNA expression55, this suggests mitochondrial
functioning and neuronal excitability in DG-like neurons
could be intimately linked, and may act synergistically to
modulate lithium response in BPAD.
Although this proposed link is circumstantial at present,
it does make intuitive sense given that neuronal excit-
ability is inherently dependent on ATP produced by the
ETC and OXPHOS pathways. It is noteworthy that in a
follow-up study using an independent sample of iPSCs,
the authors observed subtle differences in electro-
physiological measures between LR and NR DG-like
neurons58, indicating that the mechanisms driving neu-
ronal hyperexcitability in these two groups of BPAD
patients may be distinct. Strikingly, the authors were able
to use these electrophysiological differences in DG-like
neurons to predict the responsiveness of a new patient to
lithium with a success rate of over 92%. Thus, if the
proposed links between hyperexcitability, mitochondrial
functioning, and lithium responsiveness support the
notion of a discrete lithium-responsive phenotype, this
inspires genuine hope for the future of personalised
medicine in BPAD, particularly if the underlying mito-
chondrial dysregulation can be detected in the periphery
as findings from the present study suggest.
Nevertheless, as a first priority the correlation observed
in the present study between the royalblue module and
lithium response requires replication, preferably in a lar-
ger independent sample of BPAD patients. To the best of
our knowledge a genuine ‘like-for-like’ independent
replication sample with whole-blood transcriptomic data
is not currently available, and so we urge future studies to
address this gap. The closest replication sample we were
able to find, albeit with a smaller sample size, comprised
of RNA-seq data from cultured lymphoblastoid cell lines
(LCLs) derived from 24 BPAD patients; 12 LRs (total
ALDA ≥ 7) and 12 NRs (total ALDA < 7). We note that we
were unable to replicate our findings in this independent
sample using either a dichotomous or a continuous phe-
notype definition (data not shown). However, the core
mitochondrial genes of the royalblue module did not
survive the filtering process in this data set, rendering
replication unlikely, and so given the clear differences
between this sample (in vitro) and ours (ex vivo), we
believe further replication attempts in more comparable
samples are necessary.
We also urge comprehensive functional validation in
future independent replication samples to determine the
downstream effects of royalblue module dysregulation at
the mRNA level. For example, is lithium response sig-
nificantly correlated with the royalblue module at the
protein level as measured in serum or plasma? Even fur-
ther downstream than this, we suggest metabolic mea-
sures to capture ETC and OXPHOS activity, along with
MMP and mitochondrial morphology, should feature on a
panel of mitochondrial phenotypes for comparison
between better and poorer lithium responders. As already
alluded to, findings from these types of assays could prove
to be vital for informing the development of mitochon-
drial biomarkers to help predict lithium response in
BPAD.
A major limitation of the present study relates to the
cause-effect conundrum that plagues gene expression
studies in general. This issue is further compounded in
our case by the retrospective nature of our lithium
treatment response measure. For example, the measure
cannot ultimately distinguish lithium effects from
mechanisms underlying spontaneous remission from
BPAD episodes, which have been described extensively in
the historic literature59. It is not possible to disentangle
this issue based on these data alone, though genetic
association data can provide useful information. Although
mitochondrial DNA variation has so far received little
attention in relation to lithium response in BPAD, there
has been a report of a significant association between the
mtDNA 10398A polymorphism and lithium response60.
This polymorphism results in an amino acid substitution
in MT-ND3, which is one of the mitochondrially-encoded
genes comprising the royalblue module. Thus, future
work is required to determine whether the regulation of
the royalblue module may in fact be driven by mtDNA
polymorphism.
To conclude, in the present study we highlight a per-
ipheral blood co-expression module comprising 46 genes
that may be of relevance for lithium treatment response in
BPAD patients. This module is heavily enriched with
mitochondrial-related genes involved primarily in the
ETC and OXPHOS, and the expression of these genes was
found to be lower in better lithium responders relative to
poorer. Importantly, our findings are pre-validated by
previous transcriptomic studies supportive of an
Stacey et al. Translational Psychiatry  (2018) 8:183 Page 9 of 11
association not only between mitochondrially-encoded
mRNA expression levels and BPAD, but also lithium
response in BPAD. Furthermore, the apparent dysregu-
lation of the royalblue module observed here is subtle,
which speaks to the sensitivity of co-expression network
analysis approaches while underscoring the importance of
complementing traditional SNP- and gene-centric
approaches with systems biology methodology.
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